Elliott DA - Search Results

1

Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer.

Edwards DM, Sankar K, Alseri A, Jiang R, Schipper M, Miller S, Dess K, Strohbehn GW, Elliott DA, Moghanaki D, Ramnath N, Green MD, Bryant AK. Edwards DM, et al. Among authors: elliott da. Int J Radiat Oncol Biol Phys. 2024 Mar 15;118(4):963-970. doi: 10.1016/j.ijrobp.2023.09.050. Epub 2023 Oct 2. Int J Radiat Oncol Biol Phys. 2024. PMID: 37793573

2

Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.

Gharzai LA, Jiang R, Wallington D, Jones G, Birer S, Jairath N, Jaworski EM, McFarlane MR, Mahal BA, Nguyen PL, Sandler H, Morgan TM, Reichert ZR, Alumkal JJ, Mehra R, Kishan AU, Fizazi K, Halabi S, Schaeffer EM, Feng FY, Elliott D, Dess RT, Jackson WC, Schipper MJ, Spratt DE. Gharzai LA, et al. Lancet Oncol. 2021 Mar;22(3):402-410. doi: 10.1016/S1470-2045(20)30730-0. Lancet Oncol. 2021. PMID: 33662287 Free PMC article.

3

Use and Outcomes of SBRT for Early Stage NSCLC Without Pathologic Confirmation in the Veterans Health Care Administration.

Wilkie JR, Lipson R, Johnson MC, Williams C, Moghanaki D, Elliott D, Owen D, Atluri N, Jolly S, Chapman CH. Wilkie JR, et al. Adv Radiat Oncol. 2021 Apr 20;6(4):100707. doi: 10.1016/j.adro.2021.100707. eCollection 2021 Jul-Aug. Adv Radiat Oncol. 2021. PMID: 34409207 Free PMC article.

4

Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer.

Bryant AK, Sankar K, Strohbehn GW, Zhao L, Elliott D, Qin A, Yentz S, Ramnath N, Green MD. Bryant AK, et al. Lung Cancer. 2022 Jan;163:35-41. doi: 10.1016/j.lungcan.2021.11.021. Epub 2021 Dec 2. Lung Cancer. 2022. PMID: 34896803 Free PMC article.

5

Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer.

Bryant AK, Sankar K, Strohbehn GW, Zhao L, Elliott D, Daniel V, Ramnath N, Green MD. Bryant AK, et al. Int J Radiat Oncol Biol Phys. 2022 May 1;113(1):60-65. doi: 10.1016/j.ijrobp.2021.12.176. Epub 2022 Feb 1. Int J Radiat Oncol Biol Phys. 2022. PMID: 35115216 Free PMC article.

6

Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer.

Sankar K, Bryant AK, Strohbehn GW, Zhao L, Elliott D, Moghanaki D, Kelley MJ, Ramnath N, Green MD. Sankar K, et al. Cancers (Basel). 2022 Jan 26;14(3):614. doi: 10.3390/cancers14030614. Cancers (Basel). 2022. PMID: 35158881 Free PMC article.

7

Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab.

Bryant AK, Sankar K, Strohbehn GW, Zhao L, Daniel V, Elliott D, Ramnath N, Green MD. Bryant AK, et al. Int J Radiat Oncol Biol Phys. 2022 Jul 15;113(4):752-758. doi: 10.1016/j.ijrobp.2022.03.015. Epub 2022 Apr 19. Int J Radiat Oncol Biol Phys. 2022. PMID: 35450753 Free PMC article.

8

De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer.

Bryant AK, Sankar K, Zhao L, Strohbehn GW, Elliott D, Moghanaki D, Kelley MJ, Ramnath N, Green MD. Bryant AK, et al. Eur J Cancer. 2022 Aug;171:55-63. doi: 10.1016/j.ejca.2022.04.033. Epub 2022 Jun 12. Eur J Cancer. 2022. PMID: 35704975 Free PMC article.

9

Cannabis Use in Patients Seen in an Academic Radiation Oncology Department.

Cousins MM, Mayo C, Devasia T, Dykstra M, Regan S, Miller S, Allen SG, Bryant AK, Morales-Rivera K, Herr DJ, Edwards DM, Takayesu J, Birer S, Egerer N, Evans J, Elliott D, Henderson C, Laucis AM, McFarlane M, Dragovic AF, Shah J, Hayman JA, Coughlin LN, Ilgen M, Jagsi R. Cousins MM, et al. Pract Radiat Oncol. 2023 Mar-Apr;13(2):112-121. doi: 10.1016/j.prro.2022.11.002. Epub 2022 Nov 30. Pract Radiat Oncol. 2023. PMID: 36460181 Free PMC article.

10

Initial Feasibility and Acute Toxicity Outcomes From a Phase 2 Trial of ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography Response-Based De-escalated Definitive Chemoradiotherapy for p16+ Oropharynx Cancer: A Planned Interim Analysis.

Allen SG, Rosen BS, Aryal M, Cao Y, Schipper MJ, Wong KK, Casper KA, Chinn SB, Malloy KM, Prince ME, Rosko AJ, Shuman AG, Spector ME, Stucken CL, Swiecicki PL, Worden FP, Brenner JC, Schonewolf CA, Elliott DA, Mierzwa ML, Shah JL. Allen SG, et al. Among authors: elliott da. Int J Radiat Oncol Biol Phys. 2023 Sep 1;117(1):171-180. doi: 10.1016/j.ijrobp.2023.03.043. Epub 2023 Mar 16. Int J Radiat Oncol Biol Phys. 2023. PMID: 36931572 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

189 results

Search Page

Filters